ReportGem ReportGem

REAL-TIME GLOBAL RESEARCH

Jiangsu Hengrui Pharmaceuticals (1276.HK/600276.SS): Slower Innovative Drugs Sales Growth in FY26

Published: 2026-08-20Institution: CitiCompany / ticker: 1276.HK,600276.SSPages: 17Original language: English
Citi research

Research evidence excerpt

The English excerpt is extracted automatically from the cited source page and may contain layout or recognition errors. It is never batch translated.

The English excerpt is extracted automatically from the cited source page and may contain layout or recognition errors. It is never batch translated.

Open report viewer

Related research and intelligence

Dexus (DXS.AX): Resilient Core Steadies the Ship — Value Emerges at large NTA Discount but Risks Remain2026-08-20 · CitiAustralian Finance Group (AFG.AX): A solid result, yet housing slow down weigh on FY27E2026-08-20 · CitiMediatek (2454.TW): Read across from Google broadening its custom-silicon ecosystem2026-08-20 · CitiiBoxx HY Snapshot2026-08-20 · CitiUS Diversified Utilities: Texas Hearing: More Data Center Guardrails, 765kV Build to Continue2026-08-20 · CitiBrambles Limited (BXB.AX): Is execution risk manageable?2026-08-20 · Citi